Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals

被引:29
作者
Bessong, Pascal O. [1 ]
Mphahlele, Jeffrey
Choge, Isaac A.
Obi, Larry C.
Morris, Lynn
Hammarskjold, Marie-Louise
Rekosh, David M.
机构
[1] Univ Venda, Dept Microbiol, ZA-0950 Thohoyandou, South Africa
[2] Univ Limpopo, Dept Med Virol, ZA-0204 Medunsa, South Africa
[3] Natl Inst Communicable Dis, AIDS Viruis Res Unit, ZA-2131 Johannesburg, South Africa
[4] Univ Virginia, Myles H Thaler Ctr AIDS & Human Retrovirus Res, Charlottesville, VA 22908 USA
关键词
D O I
10.1089/aid.2006.22.1306
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Baseline HIV-1 resistance data are important for resistance monitoring purposes especially in regions initiating large-scale antiretroviral treatment programs. We examined 40 protease and 35 reverse transcriptase amino acid sequences of HIV-1 subtype C from drug inexperienced patients from rural settings in South Africa for resistance mutations. Samples were collected between 2001 and 2004 prior to the availability of antiretrovirals through public health institutions. Ninety-five percent of patients had no major mutations in the protease gene, although substitutions M46L (2.5%) and G73S (2.5%), which according to the Stanford Genotypic Resistance Interpretation Algorithm are considered major mutations, were detected. In addition, a high prevalence of minor mutations was observed in the protease, with at least three minor resistance-associated mutations in 37% of the isolates. An isoleucine insertion at codon 37 was detected in one sequence. Most of the RT sequences were wild-type, although V118I (8.5%) and Y318F (5.7%) associated with resistance to lamivudine and nevirapine, respectively, were observed. Our data suggest that major resistance mutations among the drug-inexperienced population in South Africa may be rare, and routine resistance testing before the initiation of therapy in this initial stage of the treatment program may not be necessary.
引用
收藏
页码:1306 / 1312
页数:7
相关论文
共 21 条
[1]   Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence [J].
Bessong, PO ;
Obi, CL ;
Cilliers, T ;
Choge, I ;
Phoswa, M ;
Pillay, C ;
Papathanasopoulos, M ;
Morris, L .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (01) :103-109
[2]   HIV-1 subtype A, D, G, AG and unclassified sequences identified in South Africa [J].
Bredell, H ;
Hunt, G ;
Casteling, A ;
Cilliers, T ;
Rademeyer, C ;
Coetzer, M ;
Miller, S ;
Johnson, D ;
Tiemessen, CT ;
Martin, DJ ;
Williamson, C ;
Morris, L .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (09) :681-683
[3]   Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa [J].
Coetzee, D ;
Hildebrand, K ;
Boulle, A ;
Maartens, G ;
Louis, F ;
Labatala, V ;
Reuter, H ;
Ntwana, N ;
Goemaere, E .
AIDS, 2004, 18 (06) :887-895
[4]  
Department of Health, 2004, NAT ANT TREATM GUID
[5]   Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors [J].
Dulioust, A ;
Paulous, S ;
Guillemot, L ;
Delavalle, AM ;
Boué, F ;
Clavel, F .
JOURNAL OF VIROLOGY, 1999, 73 (01) :850-854
[6]   Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: Implications for vaccine and antiretroviral control strategies [J].
Gordon, M ;
De Oliveira, T ;
Bishop, K ;
Coovadia, HM ;
Madurai, L ;
Engelbrecht, S ;
van Rensburg, EJ ;
Mosam, A ;
Smith, A ;
Cassol, S .
JOURNAL OF VIROLOGY, 2003, 77 (04) :2587-2599
[7]   Mutation D30N is not preferentially selected by human immunodeficiency virus type I subtype C in the development of resistance to nelfinavir [J].
Grossman, Z ;
Paxinos, EE ;
Averbuch, D ;
Maayan, S ;
Parkin, NT ;
Engelhard, D ;
Lorber, M ;
Istomin, V ;
Shaked, Y ;
Mendelson, E ;
Ram, D ;
Petropoulos, CJ ;
Schapiro, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2159-2165
[8]   Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B [J].
Grossman, Z ;
Vardinon, N ;
Chemtob, D ;
Alkan, ML ;
Bentwich, Z ;
Burke, M ;
Gottesman, G ;
Istomin, V ;
Levi, I ;
Maayan, S ;
Shahar, E ;
Schapiro, JM .
AIDS, 2001, 15 (12) :1453-1460
[9]   A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance [J].
Harrigan, PR ;
Salim, M ;
Stammers, DK ;
Wynhoven, B ;
Brumme, ZL ;
McKenna, P ;
Larder, B ;
Kemp, SD .
JOURNAL OF VIROLOGY, 2002, 76 (13) :6836-6840
[10]   A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V [J].
Hertogs, K ;
Bloor, S ;
De Vroey, V ;
Van den Eynde, C ;
Dehertogh, P ;
Van Cauwenberge, A ;
Stürmer, M ;
Alcorn, T ;
Wegner, S ;
Van Houtte, M ;
Miller, V ;
Larder, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :568-573